Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Kinathera logo — develop first-in-class oral drugs for autoimmune diseases.

Kinathera

develop first-in-class oral drugs for autoimmune diseases.

Founded 2015 France France 5 employees Seed Manufacturing, Pharmaceutical

General Information

Company Name Kinathera
Founded Year 2015
Location France France
Employees 5
Industries Manufacturing, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Kinathera. To contact Kinathera, visit kinathera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kinathera compare?

A PDF of Kinathera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kinathera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kinathera

Kinathera is a seed stage preclinical biotech startup based in France and was founded in 2015. The company's slogan is to "develop first-in-class oral drugs for autoimmune diseases." Kinathera aims to develop a unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders. The startup's primary focus is on the selective inhibition of their most advanced target, which aims to block intracellular cascades related to the ICOS receptor and inhibits type 1 interferon production. This dual approach promises enhanced control of hyperactive immune reactions in auto-immune or GvHD indications. Kinathera received its last investment in a Seed Round at 01 January 2020, and the investors at this stage have not been disclosed. The company operates within the Manufacturing and Pharmaceutical industries.

Business keywords: biotech, preclinical, autoimmune diseases, oral drugs, small chemical molecules, immune response, interferon production, immune system modulation, inflammation, GvHD, organ transplantation, drug development, autoimmune indications

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed -
01 Jan 2020

Kinathera Alternatives & Competitors

Kinathera vs
Nuvamid
Nuvamid Switzerland

A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare di...

4 employees
Health Care, Manufacturing

FAQ About Kinathera

develop first-in-class oral drugs for autoimmune diseases.
Kinathera was founded in 2015.
Kinathera is headquartered in France.
Kinathera operates in Manufacturing and Pharmaceutical. Its work centres on biotech, preclinical, autoimmune diseases and oral drugs.
Kinathera has approximately 5 employees.
Kinathera has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to Kinathera include Nuvamid. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kinathera and Nuvamid are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kinathera, https://bouncewatch.com/company/kinathera, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes